GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity
Tip: The gradual dose titration schedule (starting at the lowest dose and increasing every 4 weeks) is designed to minimize side effects
(2023) found that GLP-1 receptor agonists reduced the risk of lower limb amputation by 43% compared to sulfonylureas (HR: 0.57, 95% CI: 0.390.84), with the greatest risk reduction observed in long-term users (HR: 0.44, 95% CI: 0.270.72).(26) However, GLP-1 receptor agonists did not significantly impact diabetic foot ulcer incidence (HR: 1.08, 95% CI: 0.871.35)
B0051 1379 Artikelen Ingredinten: Acetyl L-carnitine, antiklontermiddelen: vetzuren, siliciumdioxide, magnesiumzouten van vetzuren
So if this is not a pat, a patentable, like if it's not something you could put on patent, probably there are not gonna be a lot of, uh, pharma guys who are gonna really want to invest in it because you can't protect it